Filing Analysis
📄 Other SEC Filing
Filed Jul 01, 2024
⚪ LOW
Vivos Inc. announced on June 28, 2024, that it has filed an Investigational Device Exemption (IDE) application to initiate human clinical trials for its Radiogel™ Precision Radionuclide Therapy.
📋 Key Facts
- Filed an application for an Investigational Device Exemption (IDE).
- The application is intended to authorize human clinical trials for Radiogel™ Precision Radionuclide Therapy.
- Report date: June 28, 2024; Filing date: July 1, 2024.
🚪 Officer Departure
Filed Mar 25, 2024
⚪ LOW
Vivos Inc. announced the renewal of an Executive Employment Agreement for CEO Dr. Michael Korenko, effective January 1, 2024.
🚩 Red Flags
- None identified in this specific filing; the renewal suggests management stability rather than departure.
📋 Key Facts
- CEO Dr. Michael Korenko renewed his employment agreement on December 19, 2023.
- The new term is for a period of two years, effective January 1, 2024.
- Base salary is set at $295,500 annually.
- Includes a grant of 20,000 shares of restricted stock vesting over two years in four equal installments.
- Quarterly bonus potential of up to $10,000 per quarter based on Board discretion.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.